Genentech Avastin study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Overall survival data with Genentech's VEGF-inhibitor Avastin "suggest a stronger patient benefit than anticipated," firm reports at ASCO. Bevacizumab plus chemotherapy had a median survival of 20.3 months versus 15.6 months with chemo alone in a randomized Phase III study in previously untreated metastatic colorectal cancer patients. Hazard ratio for the 50% increased chance of survival was 0.65 (p=0.00003); the study was designed to detect a hazard ratio of 0.75, or a 33% increase in chance for survival. Avastin also met the secondary endpoints of progression-free survival, response rate and duration of response. Genentech "is currently discussing plans for the filing of a [BLA] with [FDA]"...
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.